Skip to content
MarketScale
Demo
‹ Back to IndustriesSciences

The Best of CES 2019: Our Favorite Technologies

In a sea of technological innovation, it can be hard to stick out. At CES 2019 in Las Vegas, MarketScale was in search of the companies and products that are on the verge of transforming several industries. These displays in particular caught our eye: DJI Enterprise DJI, a leader in the drone industry, has been…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Bronson Anderson ·
Share

Key takeaways

01

In a sea of technological innovation, it can be hard to stick out.

02

At CES 2019 in Las Vegas, MarketScale was in search of the companies and products that are on the verge of transforming several industries.

03

These displays in particular caught our eye: DJI Enterprise DJI, a leader in the drone industry, has been…

In a sea of technological innovation, it can be hard to stick out. At CES 2019 in Las Vegas, MarketScale was in search of the companies and products that are on the verge of transforming several industries. These displays in particular caught our eye:

DJI Enterprise

DJI, a leader in the drone industry, has been winning at CES with a product that is meant for the ground. It’s Osmo Pocket handheld camera with stabilized gimbal allows users to capture flawless footage on the move.

Malta the Psycho VR

Many industries are still only learning how to utilize virtual reality to improve business. At CES 2019, Malta the Psycho is showcasing everything VR can achieve. From a roller coaster simulation to immersive gaming, this technology is poised to continue its breakout.

Segway

Segway kept CES on the move by showcasing its Ninebot lineup. Visitors to its exhibit were able to check out everything from the Segway KickScooter to the GoKart Kit as well as Loomo, a new mobile AI sidekick. Loomo uses advanced computer vision which allows the mobile assistant to follow its user around if he or she chooses to get off the device and walk.

Samsung Galaxy

Samsung did not publicly debut its much-anticipated foldable cell phone on the main stage at CES, but the company still had a tantalizing exhibition. Everything from a DJ booth to VR racing controlled by Galaxy phones gripped attendees’ attention and made for an interactive experience with Samsung’s newest products.

Omron

Automation is being implemented in almost every industry, and now ping pong can be added to the list. Omron’s AI-enabled table tennis tutor was one of the most impressive pieces of technology on the show floor. ‘Forpheus’ has been turning attendees’ heads with its natural reflexes and elite use of machine learning.

For the latest news, videos, and podcasts in the Software & Electronics Industry, be sure to subscribe to our industry publication.

Follow us on social media for the latest updates in B2B!

Twitter – @TechMKSL

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

About the author

BA
Bronson Anderson

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

BA
Bronson Anderson

For Sciences teams

See how Sciences teams use MarketScale →

Executive Thought Leadership

Explore Channels

Industry news, analysis, and expert perspectives

Professional AV›Engineering & Construction›Education Technology›Healthcare›Energy›Software & Technology›Retail›Business Services›Industrial IoT›Sports & Entertainment›Transportation›Sciences›Building Management›Food & Beverage›Architecture & Design›Hospitality›
Keep exploring

More from Sciences

Sciences hubMore expert Sciences coverage.Explore →Executive Thought LeadershipPut researchers on the record.Explore →FinThriveComplex topics, made clear.Explore →State of GEO & AI VisibilityHow B2B brands get cited by AI search.Explore →

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512